LAURA KHENG: Open Payments
NPI 1912410358 · WHITTIER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,662 in 79 payments from 11 companies in 2025. Trend: 2023 $320 · 2024 $765 · 2025 $1,662
Food & beverage: $1,563Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $349 |
| Janssen Biotech, Inc. | 12 | $311 |
| Ardelyx, Inc. | 9 | $266 |
| Madrigal Pharmaceuticals | 21 | $226 |
| Phathom Pharmaceuticals, Inc. | 5 | $154 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $140 |
| ABBVIE INC. | 3 | $63 |
| Celltrion USA Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Novo Nordisk Inc | 2 | $36 |
Products named: DUPIXENT, TREMFYA, IBSRELA, REZDIFFRA, VOQUEZNA, XIFAXAN, VEGZELMA, LINZESS.
Industry payments across CA — which companies pay providers there.
